$GEVO

Bowron Kimberly T sold $16K of GEVO

Bowron Kimberly T (Chief of Staff) sold 10,257 shares of Gevo, Inc. (GEVO) at $1.55 on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bowron Kimberly T
Published Aug 7, 2026, 9:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GEVO
Neutral
medium confidence
Mentioned
$GEVO
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GEVONeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not introduce new operational, regulatory, or financial information about Gevo.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

The article does not state whether the sale was part of a larger scheduled program cadence, nor does it provide options/other transactions that could offset the sale.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-07 after-hours; sale dated 2026-08-06

Background

This is an SEC Form 4 insider transaction disclosure for Gevo, Inc., reported by Bowron Kimberly T (Chief of Staff) as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GEVONeutralMedium confidence
Context

Gevo insider Bowron Kimberly T sold 10,257 shares in an open-market transaction at $1.5458 on 2026-08-06 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling. The article contains no new company-specific operational or financial catalyst.

Market effects

Minimal; insider sale in a single small-cap does not materially change sector fundamentals.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be read as caution about near-term risk, especially in thinly traded names.

Key entities

  • Gevo, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Bowron Kimberly T

    Chief of Staff who sold 10,257 shares at $1.5458 under a 10b5-1 plan.

Related articles

$GEVOHigh

Gevo, Inc. (GEVO): Results of Operations and Financial Condition

Gevo, Inc. (GEVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gevo_q2x2026-ex991.htm EX-99.1 Document Exhibit 99.1 Gevo Reports Second Quarter Results and Raises Financial Expectations for Full-Year 2026 ENGLEWOOD, Colo. – August 6, 2026 – Gevo, Inc. (NASDAQ: GEVO), a leader in renewable fuels, chemicals and carbon management, tod

$GEVOMedAI 8/10

Why Is Gevo (GEVO) Stock Rocketing Higher Today

Gevo (NASDAQ: GEVO) shares rose about 7.5% after the company said it expects 2026 non-GAAP Adjusted EBITDA to be more than double prior estimates. Gevo attributed the upgrade to new carbon pathways, higher production, and cost reductions, and it announced Todd Werpy, Ph.D., joining its board. The stock is volatile and trades at $1.68.

$GEVOMed

Gevo Provides Business Update and Announces Progress on Business Objectives

Gevo, Inc. (NASDAQ: GEVO) reported progress on its 2026 business objectives, aiming to potentially more than double prior estimates for non-GAAP Adjusted EBITDA by unlocking carbon pathways, debottlenecking operations, and cost improvements. It expects CFR credit sales in Q3 2026, targets over $70M in 2026 Section 45Z tax credit monetizations, and is advancing Gevo North Dakota expansion and Project Northstar. Q2 results are due Aug. 6.